Meredith Goldwasser joined Prime Medicine in September 2020 as Head of Strategy and Corporate Operations.
Dr. Goldwasser has spent the last 18 years developing new drugs in the biopharmaceutical industry working across all phases of clinical development, and in various roles in project leadership, business development and company building. She is a demonstrated strategic leader with broad experience in oncology, rare genetic diseases and data sciences. Most recently she was the development leader for the IDH Hematology program and oncology business development lead at Agios, where she also helped to build the clinical development and data sciences group. Prior to Agios, she held roles of increasing responsibility at Novartis and Genentech which contributed to the development and approval of multiple oncology products. Meredith holds a ScD in biostatistics from Harvard University, after which she worked as a research scientist at the Dana Farber Cancer Institute. She holds a BA from the University of Pennsylvania.